Skip to content

Role of Kamdugha Rasa with and without Mukta in Amlapitta.

â??Nidanatamaka (Epidemiological ) Survey of Amlapitta and Itâ??s Management by Kamdugha Rasa with and without Mukta :A Comparative Clinical Trialâ??

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025945
Enrollment
60
Registered
2020-06-17
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K279- Peptic ulcer, site unspecified, unspecified as acute or chronic, without hemorrhage or perforation

Interventions

Intervention1: Kamdugha rasa with Mukta: Patients Will be administrated with Kamdugha rasa with Mukta in a dose of 250 mg after meal twice in a day Intervention period will be of 21 days and assessmen

Sponsors

National Institute of Ayurveda Jorawar Singh Gate Amer Road Jaipur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients age above 18yrs of either sex 2.The patients with sign and symptoms of Amlapitta-Such as Avipaka,Utklesha,Hriddaha,Kanthadaha,Amlodgara,Gaurav,Aruchi etc.

Exclusion criteria

Exclusion criteria: a. Severely malnourished and debilitated patients. b. Pregnant and lactating women. c. Patients suffering from any chronic disorders or taking any longterm medications. d. Patients associated with any other serious systemic disease or complications. e. Patients suffering from haematemesis and melena. f. Patients suffering from malignancy. g. Patients suffering from Amlapitta for more than 5 years.

Design outcomes

Primary

MeasureTime frame
To assess the relief in the clinical symptoms in Amlapitta patientsTimepoint: 21 days

Secondary

MeasureTime frame
To find out causative factors involved in pathogenesis of AmlapittaTimepoint: 6 months

Countries

India

Contacts

Public ContactDrShivani Sharma

National institute of Ayurveda,Jaipur(RAJ.)

drreetusharma@gmail.com7597061958

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026